Canada's MediPharm Labs FY revenue rises 8% on international sales

Medipharm Labs

30/03/2026 12:54

Overview

Canada pharmaceutical cannabinoid maker's FY 2025 revenue grew 8% yr/yr, driven by international sales

Q4 revenue declined yr/yr

International medical cannabis revenue rose 43% yr/yr and made up over half of total revenue

Outlook

MediPharm plans continued expansion into Brazil, France and New Zealand in 2026

Company intends to optimize product mix and implement efficiencies to improve margins

MediPharm says it will maintain a disciplined approach to growth

Result Drivers

INTERNATIONAL SALES - 43% yr/yr growth in international medical cannabis revenue drove overall revenue gains, with new market entries in France, Brazil, and New Zealand

PRODUCT EXPANSION - Launches of new products, including metered dose inhalers in Australia and Canada, contributed to revenue mix and margin improvements

COST CONTROLS - Reduced operating expenses and monetization of non-core assets strengthened the balance sheet and supported margin improvement

Company press release: ID:nGNX9MhCm4

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
C$11.10 mln
C$11.82 mln (1 Analyst)

Analyst Coverage

The one available analyst rating on the shares is "hold"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)